This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "OBX-115, IL2-Sparing Engineered TIL Cell Therapy for Immune Checkpoint Inhibitor-Resistant Unresectable/Metastatic Melanoma"

16 views
June 11, 2024
0 Comments
Login to view comments. Click here to Login